Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Zientek MA"'
Autor:
Bartz Edward, Chaves Jorge, Gershtein Yuri, Halkiadakis Eva, Hildreth Michael, Kyriacou Savvas, Lannon Kevin, Lefeld Anthony, Ryd Anders, Skinnari Louise, Stone Robert, Strohman Charles, Tao Zhengcheng, Winer Brian, Wittich Peter, Zientek Margaret
Publikováno v:
EPJ Web of Conferences, Vol 150, p 00016 (2017)
During the High Luminosity LHC, the CMS detector will need charged particle tracking at the hardware trigger level to maintain a manageable trigger rate and achieve its physics goals. The tracklet approach is a track-finding algorithm based on a road
Externí odkaz:
https://doaj.org/article/8cd0ca9c9a08476cb2e8708cea36e05a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Izat N; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK., Bolleddula J; EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA., Carione P; Genentech, Inc., South San Francisco, California, USA., Huertas Valentin L; GSK R&D, Tres Cantos, Madrid, Spain., Jones RS; Genentech, Inc., South San Francisco, California, USA., Kulkarni P; Takeda Pharmaceuticals Limited, Cambridge, Massachusetts, USA., Moss D; Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium., Peterkin VC; AbbVie Inc., North Chicago, Illinois, USA., Tian DD; Eli Lilly and Company, Indianapolis, Indiana, USA., Treyer A; Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium., Venkatakrishnan K; EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA., Zientek MA; Takeda Pharmaceuticals Limited, San Diego, California, USA., Barber J; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK., Houston JB; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK., Galetin A; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK., Scotcher D; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Oct 23. Date of Electronic Publication: 2024 Oct 23.
Autor:
Subash S; College of Pharmacy and Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington 99202, United States., Singh DK; College of Pharmacy and Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington 99202, United States., Ahire D; College of Pharmacy and Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington 99202, United States., Khojasteh SC; Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California 94080, United States., Murray BP; Drug Metabolism, Gilead Sciences, Inc., Foster City, California 94404, United States., Zientek MA; Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., San Diego, California 92121, United States., Jones RS; Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, California 94080, United States., Kulkarni P; Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, United States., Zubair F; Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Inc., San Diego, California 92121, United States., Smith BJ; Terminal Phase Consulting LLC, Colorado Springs, Colorado 94404, United States., Heyward S; BioIVT, Inc., Baltimore, Maryland 21227, United States., Leeder JS; Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri 64108, United States., Prasad B; College of Pharmacy and Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington 99202, United States.
Publikováno v:
Molecular pharmaceutics [Mol Pharm] 2024 Jun 03; Vol. 21 (6), pp. 2740-2750. Date of Electronic Publication: 2024 May 08.
Autor:
Izat N; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Bolleddula J; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Abbasi A; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Cheruzel L; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Jones RS; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Moss D; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Ortega-Muro F; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Parmentier Y; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Peterkin VC; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Tian DD; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Venkatakrishnan K; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Zientek MA; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Barber J; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Houston JB; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Galetin A; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.)., Scotcher D; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK (N.I., Ji.B., J.B.H., A.G., D.S.); EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts (Ja.B., K.V.); Amgen Inc., South San Francisco, California (A.A.); Genentech, Inc., South San Francisco, California (L.C., R.S.J.); Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium (D.M.); GSK R&D, Tres Cantos, Madrid, Spain (F.O.M.); Technologie Servier, Orléans, France (Y.P.); AbbVie Inc., North Chicago, Illinois (V.C.P.); Eli Lilly and Company, Indianapolis, Indiana (D.-D.T.); and Takeda Pharmaceuticals Limited, San Diego, California (M.A.Z.) daniel.scotcher@manchester.ac.uk.
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Dec; Vol. 51 (12), pp. 1591-1606. Date of Electronic Publication: 2023 Sep 26.
Autor:
Subash S; Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington (S.S., D.K.S., D.S.A., B.P.); Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (S.C.K., R.S.J.); Drug Metabolism, Gilead Sciences, Foster City, California (B.P.M., B.J.S.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, San Diego, California (M.A.Z.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Cambridge, Massachusetts (P.K.); BioIVT Inc., Baltimore, Maryland (S.H.); and Structural Biology and Protein Sciences, Pfizer Global Research & Development and Medical, La Jolla, California (C.N.C.)., Singh DK; Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington (S.S., D.K.S., D.S.A., B.P.); Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (S.C.K., R.S.J.); Drug Metabolism, Gilead Sciences, Foster City, California (B.P.M., B.J.S.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, San Diego, California (M.A.Z.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Cambridge, Massachusetts (P.K.); BioIVT Inc., Baltimore, Maryland (S.H.); and Structural Biology and Protein Sciences, Pfizer Global Research & Development and Medical, La Jolla, California (C.N.C.)., Ahire DS; Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington (S.S., D.K.S., D.S.A., B.P.); Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (S.C.K., R.S.J.); Drug Metabolism, Gilead Sciences, Foster City, California (B.P.M., B.J.S.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, San Diego, California (M.A.Z.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Cambridge, Massachusetts (P.K.); BioIVT Inc., Baltimore, Maryland (S.H.); and Structural Biology and Protein Sciences, Pfizer Global Research & Development and Medical, La Jolla, California (C.N.C.)., Khojasteh SC; Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington (S.S., D.K.S., D.S.A., B.P.); Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (S.C.K., R.S.J.); Drug Metabolism, Gilead Sciences, Foster City, California (B.P.M., B.J.S.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, San Diego, California (M.A.Z.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Cambridge, Massachusetts (P.K.); BioIVT Inc., Baltimore, Maryland (S.H.); and Structural Biology and Protein Sciences, Pfizer Global Research & Development and Medical, La Jolla, California (C.N.C.)., Murray BP; Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington (S.S., D.K.S., D.S.A., B.P.); Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (S.C.K., R.S.J.); Drug Metabolism, Gilead Sciences, Foster City, California (B.P.M., B.J.S.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, San Diego, California (M.A.Z.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Cambridge, Massachusetts (P.K.); BioIVT Inc., Baltimore, Maryland (S.H.); and Structural Biology and Protein Sciences, Pfizer Global Research & Development and Medical, La Jolla, California (C.N.C.)., Zientek MA; Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington (S.S., D.K.S., D.S.A., B.P.); Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (S.C.K., R.S.J.); Drug Metabolism, Gilead Sciences, Foster City, California (B.P.M., B.J.S.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, San Diego, California (M.A.Z.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Cambridge, Massachusetts (P.K.); BioIVT Inc., Baltimore, Maryland (S.H.); and Structural Biology and Protein Sciences, Pfizer Global Research & Development and Medical, La Jolla, California (C.N.C.)., Jones RS; Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington (S.S., D.K.S., D.S.A., B.P.); Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (S.C.K., R.S.J.); Drug Metabolism, Gilead Sciences, Foster City, California (B.P.M., B.J.S.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, San Diego, California (M.A.Z.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Cambridge, Massachusetts (P.K.); BioIVT Inc., Baltimore, Maryland (S.H.); and Structural Biology and Protein Sciences, Pfizer Global Research & Development and Medical, La Jolla, California (C.N.C.)., Kulkarni P; Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington (S.S., D.K.S., D.S.A., B.P.); Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (S.C.K., R.S.J.); Drug Metabolism, Gilead Sciences, Foster City, California (B.P.M., B.J.S.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, San Diego, California (M.A.Z.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Cambridge, Massachusetts (P.K.); BioIVT Inc., Baltimore, Maryland (S.H.); and Structural Biology and Protein Sciences, Pfizer Global Research & Development and Medical, La Jolla, California (C.N.C.)., Smith BJ; Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington (S.S., D.K.S., D.S.A., B.P.); Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (S.C.K., R.S.J.); Drug Metabolism, Gilead Sciences, Foster City, California (B.P.M., B.J.S.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, San Diego, California (M.A.Z.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Cambridge, Massachusetts (P.K.); BioIVT Inc., Baltimore, Maryland (S.H.); and Structural Biology and Protein Sciences, Pfizer Global Research & Development and Medical, La Jolla, California (C.N.C.)., Heyward S; Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington (S.S., D.K.S., D.S.A., B.P.); Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (S.C.K., R.S.J.); Drug Metabolism, Gilead Sciences, Foster City, California (B.P.M., B.J.S.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, San Diego, California (M.A.Z.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Cambridge, Massachusetts (P.K.); BioIVT Inc., Baltimore, Maryland (S.H.); and Structural Biology and Protein Sciences, Pfizer Global Research & Development and Medical, La Jolla, California (C.N.C.)., Cronin CN; Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington (S.S., D.K.S., D.S.A., B.P.); Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (S.C.K., R.S.J.); Drug Metabolism, Gilead Sciences, Foster City, California (B.P.M., B.J.S.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, San Diego, California (M.A.Z.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Cambridge, Massachusetts (P.K.); BioIVT Inc., Baltimore, Maryland (S.H.); and Structural Biology and Protein Sciences, Pfizer Global Research & Development and Medical, La Jolla, California (C.N.C.)., Prasad B; Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, Washington (S.S., D.K.S., D.S.A., B.P.); Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California (S.C.K., R.S.J.); Drug Metabolism, Gilead Sciences, Foster City, California (B.P.M., B.J.S.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, San Diego, California (M.A.Z.); Drug Metabolism and Pharmacokinetics, Takeda Development Center Americas, Cambridge, Massachusetts (P.K.); BioIVT Inc., Baltimore, Maryland (S.H.); and Structural Biology and Protein Sciences, Pfizer Global Research & Development and Medical, La Jolla, California (C.N.C.) bhagwat.prasad@wsu.edu.
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Oct; Vol. 51 (10), pp. 1362-1371. Date of Electronic Publication: 2023 Jul 10.
Autor:
Kozminski KD; Takeda Pharmaceuticals Limited, San Diego, California (K.D.K., J.S., M.A.Z.); and BioIVT, Baltimore, Maryland (S.H.) kirk.kozminski@takeda.com., Selimkhanov J; Takeda Pharmaceuticals Limited, San Diego, California (K.D.K., J.S., M.A.Z.); and BioIVT, Baltimore, Maryland (S.H.)., Heyward S; Takeda Pharmaceuticals Limited, San Diego, California (K.D.K., J.S., M.A.Z.); and BioIVT, Baltimore, Maryland (S.H.)., Zientek MA; Takeda Pharmaceuticals Limited, San Diego, California (K.D.K., J.S., M.A.Z.); and BioIVT, Baltimore, Maryland (S.H.).
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2021 Sep; Vol. 49 (9), pp. 743-749. Date of Electronic Publication: 2021 Jun 23.
Autor:
Prasad B; Department of Pharmaceutics, University of Washington, Seattle, Washington, USA., Achour B; Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK., Artursson P; Department of Pharmacy, Uppsala University, Uppsala, Sweden., Hop CECA; Genentech, South San Francisco, California, USA., Lai Y; Gilead Sciences, Foster City, California, USA., Smith PC; Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Barber J; Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK., Wisniewski JR; Biochemical Proteomics Group, Max Planck Institute of Biochemistry, Martinsried, Germany., Spellman D; Pharmacokinetics Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., West Point, Pennsylvania, USA., Uchida Y; Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan., Zientek MA; Takeda California, San Diego, California, USA., Unadkat JD; Department of Pharmaceutics, University of Washington, Seattle, Washington, USA., Rostami-Hodjegan A; Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK.; Certara (Simcyp Division), Sheffield, UK.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2019 Sep; Vol. 106 (3), pp. 525-543. Date of Electronic Publication: 2019 Jul 26.
Autor:
Leung L; Pfizer Worldwide Research and Development; Pharmacokinetics, Dynamics and Metabolism, Groton, Connecticut (L.L., X.Y., T.J.S.), Andover, Massachusetts (M.E.D.), and La Jolla, California (M.A.Z.); Medicinal Chemistry, Cambridge, Massachusetts (A.T.), and Groton, Connecticut (J.M., M.F.B., A.M.G.); and Clinical Research, Cambridge, Massachusetts (C.B.)., Yang X; Pfizer Worldwide Research and Development; Pharmacokinetics, Dynamics and Metabolism, Groton, Connecticut (L.L., X.Y., T.J.S.), Andover, Massachusetts (M.E.D.), and La Jolla, California (M.A.Z.); Medicinal Chemistry, Cambridge, Massachusetts (A.T.), and Groton, Connecticut (J.M., M.F.B., A.M.G.); and Clinical Research, Cambridge, Massachusetts (C.B.)., Strelevitz TJ; Pfizer Worldwide Research and Development; Pharmacokinetics, Dynamics and Metabolism, Groton, Connecticut (L.L., X.Y., T.J.S.), Andover, Massachusetts (M.E.D.), and La Jolla, California (M.A.Z.); Medicinal Chemistry, Cambridge, Massachusetts (A.T.), and Groton, Connecticut (J.M., M.F.B., A.M.G.); and Clinical Research, Cambridge, Massachusetts (C.B.)., Montgomery J; Pfizer Worldwide Research and Development; Pharmacokinetics, Dynamics and Metabolism, Groton, Connecticut (L.L., X.Y., T.J.S.), Andover, Massachusetts (M.E.D.), and La Jolla, California (M.A.Z.); Medicinal Chemistry, Cambridge, Massachusetts (A.T.), and Groton, Connecticut (J.M., M.F.B., A.M.G.); and Clinical Research, Cambridge, Massachusetts (C.B.)., Brown MF; Pfizer Worldwide Research and Development; Pharmacokinetics, Dynamics and Metabolism, Groton, Connecticut (L.L., X.Y., T.J.S.), Andover, Massachusetts (M.E.D.), and La Jolla, California (M.A.Z.); Medicinal Chemistry, Cambridge, Massachusetts (A.T.), and Groton, Connecticut (J.M., M.F.B., A.M.G.); and Clinical Research, Cambridge, Massachusetts (C.B.)., Zientek MA; Pfizer Worldwide Research and Development; Pharmacokinetics, Dynamics and Metabolism, Groton, Connecticut (L.L., X.Y., T.J.S.), Andover, Massachusetts (M.E.D.), and La Jolla, California (M.A.Z.); Medicinal Chemistry, Cambridge, Massachusetts (A.T.), and Groton, Connecticut (J.M., M.F.B., A.M.G.); and Clinical Research, Cambridge, Massachusetts (C.B.)., Banfield C; Pfizer Worldwide Research and Development; Pharmacokinetics, Dynamics and Metabolism, Groton, Connecticut (L.L., X.Y., T.J.S.), Andover, Massachusetts (M.E.D.), and La Jolla, California (M.A.Z.); Medicinal Chemistry, Cambridge, Massachusetts (A.T.), and Groton, Connecticut (J.M., M.F.B., A.M.G.); and Clinical Research, Cambridge, Massachusetts (C.B.)., Gilbert AM; Pfizer Worldwide Research and Development; Pharmacokinetics, Dynamics and Metabolism, Groton, Connecticut (L.L., X.Y., T.J.S.), Andover, Massachusetts (M.E.D.), and La Jolla, California (M.A.Z.); Medicinal Chemistry, Cambridge, Massachusetts (A.T.), and Groton, Connecticut (J.M., M.F.B., A.M.G.); and Clinical Research, Cambridge, Massachusetts (C.B.)., Thorarensen A; Pfizer Worldwide Research and Development; Pharmacokinetics, Dynamics and Metabolism, Groton, Connecticut (L.L., X.Y., T.J.S.), Andover, Massachusetts (M.E.D.), and La Jolla, California (M.A.Z.); Medicinal Chemistry, Cambridge, Massachusetts (A.T.), and Groton, Connecticut (J.M., M.F.B., A.M.G.); and Clinical Research, Cambridge, Massachusetts (C.B.)., Dowty ME; Pfizer Worldwide Research and Development; Pharmacokinetics, Dynamics and Metabolism, Groton, Connecticut (L.L., X.Y., T.J.S.), Andover, Massachusetts (M.E.D.), and La Jolla, California (M.A.Z.); Medicinal Chemistry, Cambridge, Massachusetts (A.T.), and Groton, Connecticut (J.M., M.F.B., A.M.G.); and Clinical Research, Cambridge, Massachusetts (C.B.) martin.dowty@pfizer.com.
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2017 Jan; Vol. 45 (1), pp. 1-7. Date of Electronic Publication: 2016 Oct 26.
Autor:
Zientek MA; Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., San Diego, California (M.A.Z, P.K., Y.J, S.F., D.N, B.J.S.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., Groton, Connecticut (T.C.G., E.T., J.L., J.N.B, G.S.W.) michael.zientek@pfizer.com., Goosen TC; Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., San Diego, California (M.A.Z, P.K., Y.J, S.F., D.N, B.J.S.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., Groton, Connecticut (T.C.G., E.T., J.L., J.N.B, G.S.W.)., Tseng E; Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., San Diego, California (M.A.Z, P.K., Y.J, S.F., D.N, B.J.S.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., Groton, Connecticut (T.C.G., E.T., J.L., J.N.B, G.S.W.)., Lin J; Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., San Diego, California (M.A.Z, P.K., Y.J, S.F., D.N, B.J.S.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., Groton, Connecticut (T.C.G., E.T., J.L., J.N.B, G.S.W.)., Bauman JN; Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., San Diego, California (M.A.Z, P.K., Y.J, S.F., D.N, B.J.S.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., Groton, Connecticut (T.C.G., E.T., J.L., J.N.B, G.S.W.)., Walker GS; Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., San Diego, California (M.A.Z, P.K., Y.J, S.F., D.N, B.J.S.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., Groton, Connecticut (T.C.G., E.T., J.L., J.N.B, G.S.W.)., Kang P; Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., San Diego, California (M.A.Z, P.K., Y.J, S.F., D.N, B.J.S.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., Groton, Connecticut (T.C.G., E.T., J.L., J.N.B, G.S.W.)., Jiang Y; Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., San Diego, California (M.A.Z, P.K., Y.J, S.F., D.N, B.J.S.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., Groton, Connecticut (T.C.G., E.T., J.L., J.N.B, G.S.W.)., Freiwald S; Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., San Diego, California (M.A.Z, P.K., Y.J, S.F., D.N, B.J.S.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., Groton, Connecticut (T.C.G., E.T., J.L., J.N.B, G.S.W.)., Neul D; Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., San Diego, California (M.A.Z, P.K., Y.J, S.F., D.N, B.J.S.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., Groton, Connecticut (T.C.G., E.T., J.L., J.N.B, G.S.W.)., Smith BJ; Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., San Diego, California (M.A.Z, P.K., Y.J, S.F., D.N, B.J.S.); and Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer Inc., Groton, Connecticut (T.C.G., E.T., J.L., J.N.B, G.S.W.).
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2016 Jan; Vol. 44 (1), pp. 102-14. Date of Electronic Publication: 2015 Oct 28.